Table 2.
MDASI-MM and EQ-5D-3L Mean (SD) Baseline Scores in HRQoL Population, by Domain/Symptom
| Domain/Symptom | EPd | Pd |
|---|---|---|
| MDASI-MM a | n = 49 | n = 42 |
| Total symptom severity | 1.5 (1.4) | 1.6 (1.4) |
| Core symptom severity | 1.7 (1.5) | 1.7 (1.5) |
| Module symptom severity | 1.2 (1.3) | 1.4 (1.4) |
| Item 1: Pain | 2.6 (2.5) | 2.7 (2.7) |
| Item 2: Fatigue | 2.8 (2.5) | 3.0 (2.7) |
| Item 20: Bone pain | 2.3 (2.7) | 2.9 (3.0) |
| Symptom interference | 2.5 (2.7) | 2.1 (2.0) |
| Activity interference | 2.6 (2.8) | 2.8 (2.7) |
| Affective interference | 2.3 (2.7) | 1.5 (1.6) |
| EQ-5D-3L | n = 55 | n = 51 |
| Utility indexb | 0.698 (0.283) | 0.677 (0.291) |
| VASc | 65.6 (18.6) | 69.2 (20.9) |
a
Score ranges from 0 to 10, with a higher score indicating greater symptom severity/interference.
b
Score ranges from 1 (full health) to 0 (death), with negative scores (to −0.59) reflecting health states valued as worse than death.
c
Score ranges from 0 to 100, with a higher score indicating a better health status.
EPd = elotuzumab + pomalidomide + dexamethasone; EQ-5D-3L = 3-level EuroQol 5 dimension; HRQoL = health-related quality of life; MDASI-MM = MD Anderson Symptom Inventory for Multiple Myeloma; Pd = pomalidomide + dexamethasone; SD = standard deviation; VAS = visual analog scale.